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ABSTRACT: For respiratory conditions, targeted drug delivery to the lungs could produce higher local concentrations with
reduced risk of adverse events compared to systemic administration. Despite the increasing interest in pulmonary delivery, the
pharmacokinetics (PK) of drugs following pulmonary administration remains to be elucidated. In this context, the application of
modeling and simulation methodologies to characterize PK properties of compounds following pulmonary administration remains a
scarcity. Pseudomonas aeruginosa (PA) lung infections are resistant to many of the current antibiotic therapies. Targeted treatments
for pulmonary delivery could be particularly beneficial for these local conditions. In this study, we report the application of
biopharmaceutical pharmacometrics (BPMX) for the analysis of PK data from three investigational antimicrobial agents following
pulmonary administration of a suspension formulation. The observed drug concentration−time profiles in lungs and plasma of the
compound series were combined for simultaneous analysis and modeling. The developed model describes the PK data, taking into
account formulation properties, and provides a mechanism to predict dissolved drug concentrations in the lungs available for activity.
The model was then used to evaluate formulation effects and the impact of variability on total and dissolved drug concentrations in
lungs and plasma. The predictions suggest that these therapies for lung delivery should ideally be delivered in a sustained release
formulation with high solubility for maximum local exposure in lungs for efficacy, with rapid systemic clearance in plasma for
reduced risk of unwanted systemic adverse effects. This work shows the potential benefits of BPMX and the role it can play to
support drug discovery and development in pulmonary delivery.
1. INTRODUCTION
In the treatment of respiratory conditions, targeted drug delivery
to its required site of action could provide unique benefits
compared to systemic administration. Local delivery to the lungs
could achieve a higher local concentration at the target site with
reduced systemic exposure and risk of adverse events.1 For
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instance, pulmonary delivery of antimicrobial therapies could be
beneficial in the treatment of respiratory infections. For these
local treatments, the pharmacokinetics (PK) at the site of
infection in the lungs is a crucial determinant for drug efficacy.
However, despite increasing interest in pulmonary drug delivery
over the past few decades, the PK of drug molecules following
pulmonary administration remains to be elucidated. In this
context, the application of modeling and simulation to
characterize the impact of formulation behavior on local and
systemic PK following pulmonary administration remains in its
infancy.
Antibiotic resistance is a growing challenge and a major public
health threat worldwide. In particular, Pseudomonas aeruginosa
(PA), the causative bacterial species in a wide range of
pulmonary conditions, has recently developed resistance to
many of the current antibiotic therapies available.2,3 Previous
reports have indicated that about 80% of patients with cystic
fibrosis present with chronic PA lung infections.4,5 New
treatment options for these infections are therefore of much
importance. There have been ongoing efforts to explore new
targets on PA infections. To this end, the inhibition of the
quorum-sensing (QS) signaling pathway, which regulates the
production of multiple virulence factors including traits required
for PA biofilm formation and their resistance to antibiotics, has
been suggested as a promising target.3,6−9 We therefore aim to
develop a novel class of anti-virulence agents, quorum-sensing
inhibitors (QSIs), for the inhibition of biofilm formation to
sensitize PA to antibiotic treatments and attenuate its virulence.
Preclinical studies are invaluable in the lead optimization
process in order to evaluate the PK of compounds. For
pulmonary drug delivery, formulations are dosed into the lungs
of the animals. While sufficiently soluble compounds can be
administered into the lungs as solutions, poorly soluble
compounds are commonly administered as a suspension.
However, due to the dissolution of solid drug particles, the
absorption of drugs from lung to plasma depends on the
properties of the formulation, which affects both local and
systemic drug concentrations. Consequently, it could be
misleading to interpret the PK profiles of drug compounds
without taking into account the properties of the formulation
used for administration. During lead optimization and candidate
selection, PK studies are conducted to identify compounds with
the best potential for development into a clinical therapy. It is
often impractical to invest heavily in formulation development
for a specific compound in this early phase of drug discovery
when a wide range of compounds are still being considered. For
pulmonary suspensions, solubility and dissolution of drug
particles in the formulation vehicle are the major determinants
of local retention and systemic absorption. While slow
dissolution of drug particles can provide sustained drug
concentrations, only dissolved drugs are available for disposition
and activity. However, it is practically difficult to separate
dissolved drugs in lung samples following administration of a
suspension. For instance, both dissolved and undissolved drugs
will appear in an assay for homogenized lung samples. Hence, a
methodology that could support efficient PK evaluation of drug
compounds following pulmonary drug delivery taking into
account formulation properties and prediction of concentrations
of dissolved drugs in lungs would be beneficial.
In this study, we propose and report the application of
biopharmaceutical pharmacometrics (BPMX) − i.e., pharmaco-
metric modeling incorporating biopharmaceutical principles −
to support the PK evaluation of three discovery drug compounds
following pulmonary administration of a suspension. SEN023,
SEN066, and SEN089 are three novel drug molecules that are
structural analogues of a prototype QSI, which has shown
promising activity against P. aeruginosa.10 The compounds were
characterized in vitro and in vivo for their therapeutic potential
and suitability as drug candidates. The lung and plasma
concentration data of the compound series following pulmonary
administration of a suspension in rats were collected and
compiled for simultaneous analysis and modeling. The
developed model was then applied to predict concentrations
of dissolved drugs in the lung available for activity, to investigate
the potential impact of solubility and dissolution on lung and
plasma PK. The sensitivity of drug exposures to interindividual
variability on systemic clearance and formulation properties was
also evaluated.
2. MATERIALS AND METHODS
2.1. Compounds. SEN023, SEN066, and SEN089 are
structural QSI analogues designed, synthesized, and supplied by
the University of Nottingham (Nottingham, UK). The
structures of the compounds are not disclosed for intellectual
property protection since the compounds are potentially patent
pending. They are, however, structural analogues of SEN001 as
shown previously.11 Polyethylene 400 (PEG400) and poly-
sorbate 80 (PS80) were purchased from Sigma-Aldrich
(Stockholm, Sweden).
2.2. Physicochemical Properties. The physicochemical
properties of the compounds were predicted using ADMET
Predictor version 7.2 (Simulations Plus, Inc., Lancaster, CA,
USA). Two-dimensional SDF files of SEN023, SEN066, and
SEN089 were introduced into the software, and the
physiochemical and biopharmaceutical properties were calcu-
lated at pH 7.4. The physicochemical properties of the
compound series are summarized in Table 1.
2.3. Solubility Determination. The kinetic solubility was
determined by adding 5 μL of 10 mM DMSO stocks of the
compounds into 495 μL of phosphate buffer at pH 7.4. Samples
were incubated at 37 °C for >20 h, and the supernatant was
separated from the excess solid by centrifugation at 2465g
(Eppendorf Centrifuge 5810 R) for 30 min at 37 °C. The drug
concentrations in the supernatant were then determined by
liquid chromatography−tandem mass spectrometry (LC−MS/
MS). Depending on the materials available, the solubility
measurements were performed in 1−3 replicates. The fraction of
compound dissolved in the suspension formulation was
determined at Saretius (Nottingham, UK). Briefly, 1 mg of
drug was added to 2 mL of the formulation vehicle containing
PS80 and PEG400 at 2% w/v each in water, and the mixture was
stirred overnight at room temperature. The formulation was
then filtered, and the filtrate was sent to XenoGesis
Table 1. In Silico Predicted ADMET Properties of SEN023,
SEN066, and SEN089a
CPD MW
acidic
pKa
basic
pKa c log P
human jejunal permeability
(cm/s, ×104)
SEN023 368.8 none 7.1;
1.3
2.4 2.0
SEN066 383.9 10.7 1.6 3.1 4.1
SEN089 398.9 none 5.4 3.7 2.8
aAbbreviations: CPD = compound; MW = molecular weight.
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(Nottingham, UK) for analysis to determine compound
concentrations.
2.4. Metabolic Stability. Briefly, metabolic stability at 37
°C was determined in 0.5 mg/mL human and rat liver
microsomes at a compound concentration of 1 μM in 100
mMKPO4 buffer at pH 7.4 and a total incubation volume of 500
μL. The reaction was initiated by addition of 1 mM NADPH.
Samples were withdrawn after 0, 5, 10, 20, 40, and 60 min of
incubation, and the reaction was terminated by addition of cold
acetonitrile. The amount of parent compound remaining was
analyzed by liquid chromatography−tandemmass spectrometry
(LC−MS/MS). The measured clearance in the microsomes
(CLm) was then used to calculate the predicted intrinsic
clearance (CLint), hepatic clearance (CLH), and hepatic
extraction efficiency (EE) using the scaling parameters of the
respective species, as shown in eqs 1−3.
CL CL MPPGL GLPBW BWint m= · · · (1)
CL
CL fu LBF
(CL fu LBF)H
int
int
= · ·
· + (2)
EE
CL
LBF
H=
(3)
where MPPGL is milligram microsomal protein per gram liver
(46 mg/g for rat and 39.8 mg/g for human), GLPBW is gram
liver per body weight (40 g/kg for rat and 21 g/kg for human),
BW is body weight (0.25 kg for rat and 70 kg for human), fu is
fraction unbound (assumed to be 1), and LBF is liver blood flow
(13.8 mL/min for rat and 1500 mL/min for human).
2.5. Pharmacokinetics Studies. The PK study of the
compound series was performed at XenoGesis (Nottingham,
UK) and its animal research facility Saretius (Nottingham, UK).
The study protocols were reviewed and approved by the animal
ethics committee at Saretius (UKHomeOffice licence 70/8420,
19b 2). Male Sprague−Dawley (CD) rats (Charles River UK,
0.273 ± 0.048 kg (mean ± s.d.) on initiation of dosing) were
housed in groups of up to 5 prior to the study in the Saretius
animal facility. Animals were maintained under a 12 h light/dark
cycle (lights on at 07:00 h), where temperature (19−22 °C) and
humidity (45−65%) were controlled according to UK Home
Office regulations with free access to food (laboratory chow)
and water. Animals were allowed to acclimatize for at least 2 days
prior to initiation of the study.
Intratracheal dosing was performed under general anesthetic
using gaseous isoflurane (Merial Animal Health Ltd., Harlow,
UK, 5% isoflurane/95% oxygen). Briefly, rats were suspended
under anesthesia by their incisors resting on a board angled at
approximately 45°, and the tongue was gently moved aside using
forceps. A laryngoscope was then inserted to provide a clear view
of the top of the trachea, and any mucous was removed with a
cotton bub prior to insertion of the dosing needle, which is
angled to enable a clear view of the trachea during insertion.
Correct insertion of the needle was confirmed by detection of
the cartilage rings within the trachea using the needle tip before
administration of the suspension. The suspension vehicle was
composed of 2% PEG400 and 2% PS80 in water, and the
compounds were added to a concentration of 0.5 mg/mL. The
compounds were administered to the animals at a dose of 0.5
mg/kg body weight in a dose volume of 1 mL/kg. Plasma and
lung homogenate samples were collected at 0.17, 0.5, 1, 2, 3, 6,
12, and 24 h after dosing.
2.6. Analytical Methods. The amounts of drugs in the
formulation and PK samples were quantified using LC−MS/
MS. Briefly, quantitative analysis was performed using a Thermo
Scientific TSQ Quantiva triple quadrupole mass spectrometer
(Thermo Scientific, San Jose, California, USA) in positive
electrospray MRM mode coupled to a Thermo Scientific
Vanquish Binary UHPLC system (Thermo Scientific, Germer-
ing, Germany). MS ion transitions were SEN023 370 > 132 and
370 > 352, SEN066 384 > 229 and 384 > 257, and SEN089 399
> 206 and 399 > 357. The analytes were separated using an
Accucore, Phenyl-X 2.6 μm, 100 × 2.1 mm (Thermo Scientific,
Runcorn, UK) over 2.10 min using a gradient method at a
column temperature of 60 °C. The mobile phase was composed
of Milli-Q water with formic acid (0.1%) and acetonitrile with
formic acid (0.1%).
2.7. Pharmacokinetics Modeling. Initially, models were
independently developed for SEN023, SEN066, and SEN089 to
obtain parameter values for each compound. The observed
concentrations were then combined to simultaneously analyze
the lung and plasma pharmacokinetic profiles of the three drugs.
Briefly, themodel consisted of one lung compartment (L) where
doses were given and lung samples were taken, one central
compartment (C) where plasma samples were taken, one
peripheral tissue compartment (P) to describe the disposition of
drugs following systemic absorption, one solution compartment
(Dd) to describe the amount dissolved drugs, and one
suspension compartment (Ds) to describe the solid drug
particles in the dosing suspension. The total amount of drugs
in the lung compartment was the sum of drugs in the solution
and suspension compartment (Dd +Ds). Only dissolved drugs in
solution can be distributed into the systemic circulation. In
addition to the suspension compartment for dosing of the
formulation, one-, two-, three-, and four-compartment drug
disposition models were evaluated. The transfers of drug
between these compartments over time (t) are shown in eqs
4−7.
D
t
k D
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where V, CL, and Q are the volume of distribution, clearance,
and intercompartmental clearance parameters, respectively,
between the corresponding compartments and kd is the
dissolution rate constant of the solid particles in the suspension.
The structure of the final pharmacokinetic model is illustrated in
Figure 1. Clearance (CL and Q) and volume of distribution
parameters were allometrically scaled and parametrized during
the estimation as shown in eqs 8 and 9:
CL CL
WT
0.25i TV
0.75
= ·i
k
jjj
y
{
zzz
(8)
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where CLi andVi are the individual animal parameters, WT (kg)
is the animal body weight, and CLTV and VTV are the typical
clearance and volume of distribution, respectively, of an animal
with a typical body weight of 0.25 kg.
For the dissolution of the suspension particles, a first-order
dissolution and a time-varying dissolution were evaluated. For
time-varying dissolution, two functions where the dissolution
rate constant declined over time in a monoexponential and a
biexponential manner were evaluated as shown in eqs 10 and 11
k k k texp( )td d0 d 1= · − · (10)
k k k t k texp( ) exp( )t td d0 d 1 d 2= ·[ − · + − · ] (11)
where kd0 is the dissolution rate constant at time 0, representing
the baseline dissolution rate of the formulation and kdt1 and kdt2
are the first and second decline rate constants of kd. The fraction
of the dose dissolved (Fd) in the suspension, based on solubility
measurements of the formulation, determined the initial amount
of dissolved drug in the lung compartment.
In the model, the observed plasma concentrations were
predicted from the concentrations in the central compartment.
To reflect the gradual dissolution of the suspension in the lungs,
the observed lung concentrations were predicted from the total
amount of drugs in the lung compartment, as a sum of drug in
both the solution compartment and the suspension compart-
ment.
2.8. Simulation Study. The final PK model was used to
perform simulation studies to investigate the potential impact of
formulation properties on the concentration−time profiles of
total drugs in lungs, dissolved drugs in lungs, and drugs in plasma
following pulmonary administration of a suspension formula-
tion. For the simulations, key formulation parameters were
evaluated while the drug disposition parameters were fixed.
Lung and plasma PK profiles were simulated for a range of values
of initial fraction dissolved (Fd = 0.1 to 1.0) and baseline
dissolution rate constant (kd0 = 0.2 to 2.0 h
−1) parameters. The
evaluated values of Fd represent formulations containing 10 to
100% of the compounds initially dissolved and reflect the
solubility of the drugs in the formulation. The evaluated values
of kd0 represent half-lives of 0.35 to 3.47 h based on
approximation from first-order kinetics. Summary PK indices
over a 24 h period following a single dose including the
cumulative area-under-the-curve (AUC) of the PK profiles up to
24 h, maximum concentration (Cmax), and the percentage of
time over a 24 h period where the PK profiles exceeded the
target concentration (% T > target) were computed from the
simulations. Since the effective concentrations of these discovery
compounds have not been determined, for the purpose of
comparing the compounds and formulation effect in this study, 1
mg/L (i.e., 2.5 to 2.7 μM) was chosen as the target
concentration to demonstrate the application of the model.
To investigate the sensitivity of lung and plasma concen-
trations to interindividual variability (IIV) of systemic clearance
and formulation properties, simulations were performed with
variability on the parameters of interest. The predictions were
generated from a virtual population composed of 1000
simulated data sets with variability on the systemic clearance
(CLC), initial fraction dissolved (Fd), and baseline dissolution
rate constant (kd0) parameters. Since physiological and
formulation characteristics are positively constrained and
typically log-normally distributed, IIV was applied to the
parameters using an exponential model as shown in eq 12
exp( )i TVθ θ η= · (12)
where θi is the individual value of the parameter for each subject,
θTV is the typical value of the parameter in the population, and η
is normally distributed with a coefficient of variance (CV) of
50% and mean 0.
2.9. Data Analysis and Software.Model development was
performed in the nonlinear mixed-effects modeling software
program, NONMEM (version 7.4; ICON Development
Solutions),12 using the Laplacian estimation with interaction
algorithm. Perl-speaks-NONMEM (PsN) was used for model
execution and generation of visual predictive checks (VPCs).13
R (version 3.6; R Foundation for Statistical Computing, Vienna,
Austria) was used for data management, and the Xpose4
package14 was used to support graphical evaluation of results for
model diagnostics. The run records and numerical comparison
of models were maintained and facilitated by Pirana.15
The likelihood ratio test (LRT) was used to evaluate statistical
significance for inclusion of additional parameters in nested
models, where the objective function value (OFV) was assumed
to be χ2 distributed. A decrease in OFV of 3.84 between nested
models with one parameter difference was considered to be a
statistically significant difference at the 5% significance level.
Model development was guided by the scientific plausibility of
the parameter estimates, the change in objective function value
(ΔOFV), parameter precision, and evaluation of goodness-of-fit
and residual diagnostic plots including the simulation-based
VPCs.16
Since the majority of samples were terminal samples and the
primary interest of central tendency in the preclinical study, IIV
of the parameters was not estimated. For VPCs, 1000 data sets
were simulated from the final parameter estimates using the
original data set as a template. The predicted medians and the
2.5th and 97.5th percentiles and their corresponding 95%
confidence intervals were computed from the simulated data and
Figure 1. Schematic diagram showing the structure of the final
pharmacokinetic model. Abbreviations: CLC = central clearance; CLLC
= distribution clearance from lung to central compartment; Q =
intercompartmental clearance; C = central compartment; L = lung
compartment; P = peripheral tissue compartment; Dd = solution
compartment for dissolved drugs; Ds = suspension compartment for
solid drug particles in the suspension; Fd = fraction dissolved; kd =
dissolution rate constant, where kd = kd0·(e−kdt1·t + e−kdt2·t), and kd0 =
dissolution rate constant at time 0, kdt1 = first decline rate constant of kd,
and kdt2 = second decline rate constant of kd.
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overlaid with the observed values. Data below the lower limit of
quantification (LLOQ) were handled using the likelihood-based
M3 method.17 The observed data were natural log-transformed
for model development (i.e., the transform-both-side approach),
and a proportional error model, as approximated by a natural
log-transformed additive error model, was used to describe the
residual unexplained variability.
For the simulation study, prediction and visualization of
results were performed in R. The mrgsolve package (version
0.9.0;MetrumResearchGroup, USA)18 was used to perform the
simulations. The shiny package (version 1.2.0; RStudio, USA)19
was used for application development to support interactive
evaluation and visualization of the simulation output.
3. RESULTS
3.1. Solubility Determination. The kinetic solubility
measurements of SEN023, SEN066, and SEN089 in the
formulation used were 16.4, 14.9, and 27.3 μg/mL, respectively.
The results were consistent with the rank order observed in the
suspension formulation, in which the fractions of SEN023,
SEN066, and SEN089 dissolved were 10, 5, and 21%,
respectively. These solubility values were included in the PK
model.
3.2. Metabolic Stability. The metabolic stability of the
compounds in human and rat liver microsomes are summarized
in Tables 2 and 3. The results showed that the compounds were
all likely to be rapidly metabolized in rats after systemic
absorption with high hepatic extraction efficiency (EE) ranging
from 0.72 to 0.86. However, the compounds were more stable in
human than in rat liver microsomes, with their EE ranging from
0.34 to 0.72, suggesting that these compounds might be less
extensively metabolized in humans.
3.3. Plasma Pharmacokinetics Following Pulmonary
Administration. Following pulmonary administration of the
suspension, the compounds were rapidly distributed into the
systemic circulation as shown by the rapid appearance of the
drugs in plasma and the lack of a distinct absorption phase in the
plasma concentration−time profiles (Figure 2). Among the
three compounds, the plasma concentration of SEN089
declined most rapidly, with a steep distribution phase that
lasted throughout the sampling period. In contrast, following the
initial distribution phase, the decline of SEN066 was the slowest
as characterized by a relatively flat plasma concentration−time
profile after 6 h.
3.4. Lung Pharmacokinetics Following Pulmonary
Administration. The lung concentrations of the compounds
declined slowly following pulmonary administration of the
suspension and remained in the lungs at high concentrations
over the sampling period (Figure 2). The lung concentrations of
SEN089 declined most rapidly, while the ones of SEN066 lasted
the longest in the lungs. It is worth noting that themeasured lung
concentrations of the compounds were more than 2 orders of
magnitude higher than their plasma concentrations. The lung
concentration−time profiles also declined slower than their
plasma profiles, indicating that the measured concentrations in
lung and plasma were not at equilibrium.
3.5. Pharmacokinetics Modeling. The observed concen-
trations of the compounds were described by the final model
with acceptable fit and predictive performance as demonstrated
in the VPC (Figure 2). While a peripheral tissue compartment
was needed to describe the observed concentrations for
SEN089, it did not improve the model fit for SEN023. Although
an additional peripheral tissue compartment improved the
model fit for SEN066, parameter estimates became physiolog-
ically implausible. Further investigation revealed that the
difference in model fit was primarily contributed by the limited
plasma samples at 24 h, and there was no improvement when
these samples were excluded. The peripheral tissue compart-
ment was therefore not included in the final model for SEN066.
Thereafter, the addition of a deep lung compartment to the
model before systemic absorption did not further improve
model fit for any of the compounds.
For the formulation components of themodel, the fractions of
the nominal dose in solution were fixed to the values determined
in the solubility study. Dissolution of solid particles was
described by the release of drugs from the suspension
compartment to the solution compartment in the lung, in
which the dissolved drugs in solution were available for systemic
absorption and distribution. For the dissolution process,
compared to a typical first-order kinetics, the time-varying
dissolution rate constant in the final model improved model fit
for all of the compounds significantly (p < 0.001, ΔOFV for
SEN023 = −95.2, SEN066 = −78.1, SEN089 = −81.9).
Compared to a monoexponential decline, a time-varying
dissolution rate constant with a biexponential decline further
improved model fit significantly (p < 0.01−0.001, ΔOFV for
SEN023 = −15.5, SEN066 = −22.7, SEN089 = −17.5). The
parameter estimates of the final model and their relative
standard errors are summarized in Table 4.
3.6. Formulation Effects on Drug Exposures in Lungs
and Plasma. The predicted lung and plasma PK profiles
resulting from suspension formulations with different initial
fractions of drugs dissolved and varying dissolution rates are
shown in Figure 3. The simulation results showed that increasing
the initial amount of dissolved drugs in the suspension would
increase the amount of drugs available for rapid distribution
from lung to plasma immediately after administration, leading to
higher initial plasma concentrations. For a given drug, the
concentrations in lungs and plasma then declined at the same
rate for all suspension formulations after the rapid initial
distribution phase. When the formulation was a complete
solution (i.e., Fd = 1), the initial concentrations in both lungs and
plasma declined much more rapidly than any suspension
formulations, reaching the terminal elimination phase in less
than 2 h after administration. The results also showed that
Table 2. Metabolic Stabilities of SEN023, SEN066, and
SEN089 in Rat Liver Microsomesa
CPD half-life (min) CLint (mL/min) CLH (mL/min) EE
SEN023 18.14 35.15 9.91 0.72
SEN066 11.26 56.63 11.10 0.80
SEN089 7.50 85.07 11.87 0.86
aAbbreviations: CPD = compound; CLint = intrinsic clearance; CLH =
hepatic clearance; EE = extraction efficiency.
Table 3. Metabolic Stabilities of SEN023, SEN066, and
SEN089 in Human Liver Microsomesa
CPD half-life (min) CLint (mL/min) CLH (mL/min) EE
SEN023 67.51 1201.17 667.03 0.44
SEN066 106.73 759.72 504.30 0.34
SEN089 21.25 3816.07 1076.76 0.72
aAbbreviations: CPD = compound; CLint = intrinsic clearance; CLH =
hepatic clearance; EE = extraction efficiency.
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increasing dissolution rate would lead to a more rapid decline of
drug concentrations in both lungs and plasma due to faster
distribution of the compounds to the systemic circulation, after
which they were rapidly metabolized by the liver. However, peak
concentrations in plasma increased with dissolution rate before
the more rapid decline.
Drug exposures, as demonstrated by the PK indices, resulting
from suspension formulations with different initial amounts of
dissolved drugs and dissolution rates, are shown in Figures 4−6.
The results showed that after 24 h following a single dose, AUCs
of the total lung and the plasma concentration−time profiles
would both increase with decreased initial fraction of dissolved
drugs in the suspension. However, AUC of the dissolved drugs
in lungs would increase with solubility. In contrast, slower
dissolution would lead to higher AUC for total drugs in lungs but
lower AUCs for dissolved drugs in lungs and drugs in plasma.
The AUC of total drugs in lungs was most affected by the range
of solubility and dissolution rates evaluated, with a 39-, 57-, and
47-fold change for SEN023, SEN066, and SEN089, respectively,
across the formulation design space. In contrast, the changes of
AUCs for dissolved drugs in lungs and drugs in plasma ranged
from 2.0 to 2.4 and from 1.1 to 1.4, respectively.
In the predictions, the peak concentrations of dissolved drugs
in lungs and drugs in plasma increased with increasing solubility
and dissolution rate. Within the study design space, the Cmax of
the compounds in plasma changed by about 7-fold, increasing
Figure 2. Visual predictive check of the final pharmacokinetic model showing the observed lung and plasma concentrations of SEN023, SEN066, and
SEN089 with the observed median and the 2.5th and 97.5th percentiles following intratracheal administration of the suspension formulation and their
corresponding 95% confidence intervals computed from the simulated data (shaded).
Table 4. Parameter Estimates and Relative Standard Errors (RSE %) of the Final Modela
parameter unit description SEN023 RSE % SEN066 RSE % SEN089 RSE %
CLLC mL/min clearance − lung to central 1.19 47.2 1.16 9.1 2.06 45.7
VL mL volume of distribution − lung 3.22 11.6 3.29 12.2 5.97 14.5
CLC mL/min clearance − central 6.33 7.2 11.9 11.2 2.51 8.4
VC mL volume of distribution − central 47.9 30.7 34.2 12.1 12.7 18.9
Q mL/min intercompartmental clearance -- -- -- -- 0.0483 46.6
VP mL volume of distribution − peripheral -- -- -- -- 17.7 45.0
Fd -- initial fraction dissolved 0.10* -- 0.05* -- 0.21* --
kd0 h
−1 baseline dissolution rate constant 0.304 9.6 0.235 11.4 0.806 4.4
kdt1 h
−1
first decline rate constant of kd 0.687 35.4 1.32 14.2 1.16 7.4
kdt2 h
−1 second decline rate constant of kd 0.0582 14.6 0.12 8.0 0.138 10.6
ERRPL % proportional error − plasma 45.9 9.2 77.1 9.3 43.9 6.5
ERRLG % proportional error − lung 39.4 17.7 34.2 25.3 55.0 15.8
aNB: Clearance and volume of distribution parameters are apparent pharmacokinetic parameters following intratracheal administration and
allometrically scaled to 0.25 kg for a typical rat as shown in eqs 8 and 9. Asterisk denotes fixed parameters.
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with initial fraction dissolved. The peak concentrations of total
drugs in lungs occurred immediately after dosing and were
independent of formulation properties, while peak concen-
trations of dissolved drugs in lungs were dependent only on
solubility. Low solubility and slow dissolution were also
predicted to increase % T > target in lungs. However, the
range of solubility and dissolution rates influenced the % T >
target of dissolved drugs in lungs and drugs in plasma differently
for the three compounds. The % T > target value in plasma
increased with increasing solubility and dissolution rate for
SEN023 and SEN066. For SEN089, however, low solubility and
fast dissolution led to increased T > target in plasma. For
dissolved drugs in lungs, while the overall % T > target values
were low in all scenarios, low solubility with a moderate
dissolution rate resulted in the highest % T > target for all of the
compounds. The PK indices of the compounds are summarized
in Table 5.
3.7. Impact of Interindividual Variability on Drug
Exposures in Lungs and Plasma. The predicted lung and
plasma PK profiles taking into account IIV on systemic
clearance, solubility, and dissolution rate of the formulation
are shown in Figure 7. The results showed that only plasma drug
exposure, and dissolved drugs in lungs to a small extent, but not
the exposure of total drugs in lungs, was sensitive to variability in
systemic clearance. Both plasma and lung exposures were
insensitive to IIV of solubility of the drug in the formulation at
the level of variability evaluated. Drug exposures were most
sensitive to IIV of dissolution rate in the formulation, which was
predicted to impact both lung and plasma drug exposures.
Among the compound series, SEN089 was the most sensitive to
the IIV of dissolution rate while SEN066 was the least sensitive
to it.
4. DISCUSSION
This study set out to explore the application of BPMX in
preclinical drug evaluation given the typical constraints in a drug
discovery setting, based on our investigation of the PK of three
prototype QSIs following pulmonary administration. Due to the
limited solubility, the compounds were administered into the
lungs as a suspension formulation. The suspension allowed
administration of doses higher than the aqueous solubility and
provided a sustained release of compounds in lungs. Drug
absorption and clearance from lungs are typically rapid, leading
to a short residence time in lungs with low local drug exposure. If
high drug concentration in lungs is desirable for a local effect,
sustained release formulations as exemplified here by a
Figure 3. Predicted concentration−time profiles of SEN023, SEN066, and SEN089 in the lung (total and dissolved) and plasma resulting from
formulations with different values of (a) initial fraction dissolved (Fd) and (b) baseline dissolution rate (kd0).
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suspension could be beneficial. The relatively simple formula-
tion vehicle used in this study was established previously to
improve solubility of the compound series with excipients that
have been shown to be suitable for lung administration.11,20−22
The local and systemic PK profiles of drugs were dependent
on the solubility of the compound in the formulation and the
dissolution of particles in the suspension. Despite the influential
roles of these formulation properties, extensive investment in
formulation development for each compound during this early
phase of drug discovery is often not feasible due to time
constraints and limited availability of compounds, typically in
batch sizes of milligrams in a laboratory. The compound is then
prioritized for different assessments such as in vitro absorption,
distribution, metabolism, and excretion (ADME) assays,
formulation, and PK studies. Another limiting factor when
working with formulations intended for pulmonary admin-
istration is that it is often difficult to determine dissolved drug
concentrations in lungs available for activity. Hence, a
methodology that can support efficient evaluation of local and
systemic PK following pulmonary administration, with
predictive capacity of dissolved drug concentrations in lungs,
taking into account the biopharmaceutical effects of formulation
properties could be beneficial.
The three compounds in the present study were all poorly
water soluble and lipophilic, with their c log P values ranging
from 2.4 to 3.7. It was expected that the excipients in the
formulation vehicle would increase the solubility of the
compound series as previously shown with the analogues.11
However, despite the use of the formulation medium, only 5 to
21% of the compounds were dissolved when prepared at a
concentration of 0.5 mg/mL. The compounds were therefore
given as a suspension formulation into the lungs of the animals.
Following pulmonary administration, the compounds were
rapidly absorbed into the systemic circulation as seen by the
immediate appearance of the drugs in plasma and the lack of a
distinct absorption phase. Previous analogues of the compounds
have been shown to be rapidly absorbed when given as a solution
formulation.11 The results in the present study showed that
these compound analogues were easily absorbed even when
given as a suspension formulation. Such rapid absorption has
Figure 4. The predicted (a) area-under-the-curve at 24 h (AUC), (b) maximum concentration (Cmax), and (c) fraction of time above the target
concentration (% T > target) over a 24 h period of SEN023 in lungs and plasma resulting from a range of initial fractions dissolved (Fd) and baseline
dissolution rate constants (kd0). The shade of the color represents the values in the formulation design space explored where dark purple is highest and
white is lowest.
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also been reported with other antimicrobial agents.23−27 This is
consistent with the high absorptive capacity of lungs given the
large surface area and the thin alveolar epithelium linings.28−30
From the PK profiles, it was evident that the drug
concentrations in lungs and plasma declined at different rates.
This lack of parallelism indicated that the observed drug
concentrations in lungs and plasma were not at distribution
equilibrium. Given the rapid distribution between lung and
plasma, the sustained and slow decline of the observed lung
concentrations reflected the gradual dissolution of drugs in the
suspension. Drug dissolution in suspension formulations has
been shown to be the rate-limiting step in absorption using an
isolated perfused rat lung model.31 The present study provided
further insight into this phenomenon in vivo by investigating the
lung and plasma PK profiles following pulmonary administration
of a suspension formulation. However, since whole lung samples
were collected, both dissolved and undissolved drugs in the
suspension would have appeared in the sample assays. The
dissolution of drug in lungs is a dynamic process. It is not
straightforward to determine concentrations of dissolved drugs
in lungs available for activity and disposition. It would have
required special sample handling and separation of any
remaining drug particles in the lung samples with specific assays
to capture and quantify the undissolved and dissolved drugs at
each time point. Hence, we developed a BPMX model to
describe the PK profiles and predict dissolved drug concen-
trations in lungs as a function of formulation properties.
Ideally, comprehensive comparison of the compounds would
have required substantial investment to develop multiple
formulations for each compound across the vast chemical and
formulation design space with subsequent in vivo studies to
thoroughly evaluate the PK of these compounds and
formulations. In the present study, the modeling approach
helped to maximize the information obtained from the study by
supporting the analysis and interpretation of the data, taking into
account the properties of the formulation used in the study. The
model allowed prediction of the potential PK of the compounds
across the formulation design space in a semimechanistic
manner for inference and compound comparison when
exhaustive testing is not practically feasible. Although the
Figure 5. The predicted (a) area-under-the-curve at 24 h (AUC), (b) maximum concentration (Cmax), and (c) fraction of time above the target
concentration (% T > target) over a 24 h period of SEN066 in lungs and plasma resulting from a range of initial fractions dissolved (Fd) and baseline
dissolution rate constants (kd0). The shade of the color represents the values in the formulation design space explored where dark purple is highest and
white is lowest.
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comparison of sampling methods is beyond the scope of this
study, it is worth noting that the implications resulting from the
use of tissue homogenates have been discussed.32 Without
endorsing a specific sampling method, the present study focused
on investigating the potential application of semimechanistic
Figure 6. The predicted (a) area-under-the-curve at 24 h (AUC), (b) maximum concentration (Cmax), and (c) fraction of time above the target
concentration (% T > target) over a 24 h period of SEN089 in lungs and plasma resulting from a range of initial fractions dissolved (Fd) and baseline
dissolution rate constants (kd0). The shade of the color represents the values in the formulation design space explored where dark purple is highest and
white is lowest.
Table 5. Summary of PK Indices across the Study Design Space for SEN023, SEN066, and SEN089a
CPD AUCLT AUCLD AUCPL CMXLT CMXLD CMXPL TATLT TATLD TATPL
(μg/L·h) (μg/L) (%)
SEN023 max 222131.3 5720.5 395.1 46583.9 46583.9 1613.1 100.0 3.4 0.7
min 5720.5 2696.3 347.3 46583.9 4658.4 209.0 1.1 0.7 0.0
ratio 38.8 2.1 1.1 1.0 10.0 7.7 90.9 4.9 NA
SEN066 max 314073.5 5545.2 205.3 45592.7 45592.7 1101.1 100.0 3.0 0.4
min 5545.2 2289.3 148.1 45592.7 4559.3 153.5 0.9 0.6 0.0
ratio 56.6 2.4 1.4 1.0 10.0 7.2 111.1 5.0 NA
SEN089 max 182530.9 3881.0 985.4 25125.6 25125.6 4002.7 100.0 3.2 1.7
min 3881.0 1965.3 796.1 25125.6 2512.6 531.6 1.5 0.6 0.0
ratio 47.0 2.0 1.2 1.0 10.0 7.5 66.7 5.3 NA
aAbbreviations: CPD = compound; AUC = area-under-the-curve at 24 h; CMX = maximum concentration; TAT = %T > target; LT = total lung
drug concentrations; LD = dissolved lung drug concentrations; PL = plasma drug concentrations; NA = not applicable.
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pharmacometric models to support compound selection in a
drug discovery setting.
The developed model described both the central tendency
and the variability of the observed drug concentrations in lungs
and plasma for the three compounds with good predictive
performance as shown by the VPC. Since whole lung samples
were collected in the study, clearance mechanisms within the
lung, e.g., mucociliary clearance and macrophages, were not
considered in the model separately. The study was neither
sufficiently powered with spatial resolution to distinctively
identify these mechanisms nor was this the objective of the
study. Therefore, the clearance described in the model reflects
the net clearance of the drug as observed in the study. From the
model parameters, SEN089 seemed to be the most widely
distributed into peripheral tissue, as reflected by the additional
distribution compartment. During model development, the
solubility of the compounds in the formulation, as reflected by
the fraction of drugs initially dissolved in the suspension, were
included in the model. This information helped maintain model
identifiability and allowed the estimation of the in vivo
dissolution parameters. SEN089, being the most soluble
compound in the formulation, had the highest baseline
dissolution rate constant in the model. In contrast, the solubility
of SEN023 and SEN066 was lower than that of SEN089 in the
formulation with a lower baseline dissolution rate constant in the
model. Importantly, the model was not able to describe the data
when first-order kinetics was used to describe the dissolution
process. Instead, a time-varying rate constant, which declined
over time, was needed to describe the observed concentrations.
In particular, a dissolution rate constant with a biexponential
decline significantly improved the model fit. This suggests that
the in vivo dissolution process observed was a complex
phenomenon with potentially subpopulations of particles
dissolving at different rates. This could be caused by the range
of particle sizes as they dissolved at different rates and/or the
regional distribution of drugs in the airways leading to different
dissolution and clearance of the drugs. It should be noted that
the suspension used in this study was not a controlled
suspension with a narrow particle size distribution, but a rather
coarse suspension of the material as received thoroughly
dispersed and stirred overnight prior to administration. As a
coarse approximation from visual examination, we estimated the
particle size of the visible materials to be around 50−100 μm.
The small quantities of the QSIs restricted the development of
controlled suspensions through ball milling or ultrasonica-
tion.33,34 For such formulations, typically larger volumes need to
be prepared than the ones prepared herein, and much material is
lost during processing.
The developed PK model was used to evaluate the potential
impact of formulation properties on local and systemic PK of the
drugs. From the predicted PK profiles, the role of suspension
formulations in providing sustained concentrations in lungs was
clearly demonstrated. When the solubility parameter (Fd) of the
model increased from 0.1 to 0.9, the absorption of drugs from
lung to plasma became increasingly rapid, as shown by the
sharper peak concentrations in plasma. However, following the
initial distribution, drugs in plasma were also more rapidly
cleared leading to lower concentrations in both lung and plasma
with higher solubility in the formulation. After initial absorption
of the dissolved drugs, drug concentrations declined at the same
rate regardless of solubility. When the drug was completely
dissolved in the formulation (i.e., Fd = 1), the concentrations in
both lung and plasma declined much more rapidly than the ones
resulting from suspension formulations and decreased by more
Figure 7. Predicted lung and plasma concentration−time profiles of SEN023, SEN066, and SEN089 and their corresponding 95% prediction intervals
(shaded) with interindividual variability on (a) systemic clearance, (b) solubility, and (c) baseline dissolution rate constant.
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than 3 orders of magnitude within 2 h. This was consistent with
the rapid absorption and clearance observed when the analogues
of the compound series were administered as solution
formulations to the lungs.11 Without the sustained release
properties resulting from the slow dissolution of drug particles,
drugs in solution were rapidly absorbed and cleared systemically.
The high metabolism, as suggested by the results from the rat
liver microsome study, likely also contributed to the rapid
systemic clearance. It should be noted that, in contrast to
systems pharmacology-based models that are developed to
quantitatively describe a biological or disease process with less
emphasis on describing specific observations, if they are
available at all, pharmacometric models as applied in the present
study are data-driven, relying on robust statistical models and
algorithms derived to describe the available data, and models are
rigorously assessed for their ability to reproduce the
observations.35 The measured metabolic stability values were
therefore not specifically included as a parameter in this model.
The results of the metabolic stability study, however, provided
insight into the potential clearance mechanisms of these
compounds in vivo.
It was apparent from the predictions that lung concentrations
declined at a faster rate with increased dissolution rate, causing a
more rapid absorption and an increase in initial plasma
concentrations. However, this was also followed by a faster
decline of plasma concentrations after absorption. In contrast,
slower dissolution led to more sustained concentration−time
profiles in both lung and plasma, despite the slower systemic
absorption and lower peak concentrations in plasma. This
suggests that a sustained-release lung formulation is expected to
provide sustained plasma concentrations, which could impact
systemic exposure for therapeutic effect or toxicity, depending
on the target site of treatment. SEN023 and SEN066, being the
less widely distributed compounds in peripheral tissues
compared to SEN089, were more susceptible to changes in
the baseline dissolution rate. Their plasma concentrations
declined more rapidly with increasing baseline dissolution rate
than SEN089. This rapid decline could be further contributed by
the increased availability of drugs for systemic clearance due to
the relatively low tissue distribution. The decline of dissolved
drug concentrations in lungs mirrored the concentrations in
plasma for the compound series, consistent with the rapid
distribution between lung and plasma.
To evaluate formulation effects on overall drug exposures, we
computed the AUC, Cmax, and % T > target over a 24 h period as
a function of both solubility and dissolution rate of the
compounds in the formulation. Similar metrics have long been
used for the calculation of PK/PD indices to relate drug
concentrations and efficacy of antimicrobial drugs.36−39 From
the predictions, it was evident that low solubility and slow
dissolution would lead to maximum total drug exposure in lungs
as shown by the local AUC and % T > target. However, high
solubility was needed for maximum dissolved drug exposure in
lungs for activity. In contrast, for systemic drug delivery, low
solubility with fast dissolution was expected to lead to maximum
drug exposure after 24 h as demonstrated by the plasma AUC.
The AUC of total drugs in lungs increases with decreasing initial
fraction dissolved since undissolved drugs stay in the lung longer
than dissolved drugs. The net outcome is slower but more
sustained absorption from the lung into the systemic circulation,
resulting in a lower peak plasma concentration but a more
sustained plasma concentration−time profile and hence a higher
AUC. Conversely, the AUC of dissolved drugs in lungs is
directly related to solubility and the initial fraction of dissolved
drugs. Higher solubility leads to higher concentrations of
dissolved drugs and therefore higher AUC. Hence, treatments
for local conditions such as these QSIs may be engineered to
minimize unwanted systemic drug exposure and adverse effects.
The results suggest that, depending on the target site of action,
systemic and local drug exposures may be optimized for maximal
efficacy and safety. Hence, if the compounds are intended for
local conditions in lungs, as in the case of chronic lung infections,
a sustained-release formulation with high solubility and slow
dissolution could be preferable. In contrast, for systemic
treatment, a formulation with low solubility and fast dissolution
would be beneficial. While this is the ideal scenario, it is worth
acknowledging the formulation challenge since highly soluble
compounds tend to have fast dissolution rates. Therefore,
sustained-release formulations with careful design would be
needed to implement such a drug delivery strategy. For example,
dry powder inhaler formulations with sophisticated particle
engineering and design using spray-drying could play a valuable
role here.40,41
It should be noted that the AUC at 24 h in plasma was only
moderately affected by formulation properties with a maximum
of 1.4-fold difference across the formulation design space in the
study. In contrast, the AUC of total drug concentrations in lungs
was much more susceptible to changes in formulation
properties, differed by 39- to 57-fold for the scenarios evaluated.
Interestingly, peak concentrations in lungs and plasma were
affected differently by these formulation properties. Cmax in
plasma differed by about 7-fold for all of the compounds across
the study design space. It increased with both solubility and
dissolution rate and was most affected by solubility. In contrast,
Cmax of total drug concentrations in lungs was independent of
formulation properties and was only dictated by the dose. The
effect of formulation on % T > target of total drugs in lungs was
most dramatic, differed by >111-fold for SEN066 and ranging
from <1 to 100% for the three compounds. In contrast, % T >
target in plasma was barely affected, ranging from 0 to 1.7% for
the three compounds. Overall, despite their effect on Cmax in
plasma, formulation properties were much more influential on
drug exposure in lungs, both total and dissolved, than in plasma,
as indicated by the much wider range of AUC and % T > target
values for total drug concentrations in lungs. It should be noted
that the objective of the present study was to demonstrate an
application of BPMX in a drug discovery setting and hence
focused on only the PKmetrics at 24 h following a single dose for
comparison. Other metrics such as exposures after repeated
dosing at a later time-point may be more appropriate for other
therapies. Further studies should be considered to more
thoroughly evaluate these drug delivery strategies for other
treatments and chronic therapies.
From the metabolic stability results, it was apparent that the
metabolism of the compounds was variable and species-
dependent as noted by the different metabolism in human and
rat liver microsomes. In addition, formulation properties
including solubility and dissolution measurements are known
to be variable depending on experimental conditions. The
developedmodel was therefore used to evaluate the sensitivity of
lung and plasma exposures to IIVs on systemic clearance and
formulation properties. It was clear that IIV on systemic
clearance only impacted plasma concentrations with a negligible
effect on lung concentrations. This is consistent with previous
results reported with an earlier series of QSI analogues.11 For
formulation properties, IIV on solubility had a limited influence
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on drug concentrations in both lungs and plasma, likely due to
the low solubility of the compounds. SEN089, the most soluble
compound in the series, was most affected by IIV in solubility. In
contrast, IIV on the dissolution rate parameter was much more
influential than on solubility and impacted drug concentrations
in both lungs and plasma. In fact, IIV of the dissolution rate
parameter was the major contributor resulting in variability of
drug concentrations in all scenarios. This reflects the importance
of dissolution as a rate-limiting step in drug absorption since the
compounds were administered at a concentration higher than
their solubility in the suspension. The finding highlights the
potential impact of variability in dissolution studies and how this
uncertainty should be considered when interpreting measure-
ments. It also indicates the importance of careful particle
engineering for consistent dissolution rates of formulations
designed for pulmonary delivery. The results resonate with
previous work in the literature that suggests that dissolution is
the rate-limiting step governing the systemic absorption rate for
lipophilic drugs with low solubility following pulmonary
administration.42 This supports that the modeling approach
adopted in the present study is appropriate and has the potential
to be more broadly applicable to inform the development of
other treatments.
5. CONCLUSIONS
This study has demonstrated an application of BPMX and how it
can be a valuable tool to inform drug discovery and development
in pulmonary delivery. The modeling approach supported
quantitative evaluation of the PK properties of the investiga-
tional compounds following pulmonary administration of a
suspension formulation, given the available data and constraints
typically encountered in such a preclinical setting. The
developed model adequately described the PK data in lungs
and plasma, taking into account formulation properties of the
suspension, and thus allowed the prediction of dissolved drug
exposure in lungs as a function of formulation properties.
Depending on the target site of drug action and PK driver for
efficacy, formulations can be engineered for optimal drug
exposure accordingly for maximal efficacy and safety. The results
suggest that these QSI treatments designed for pulmonary
delivery should ideally be given in a sustained-release
formulation with high solubility and slow dissolution for
extended local residence time and exposure and rapid clearance
after absorption into the systemic circulation. Similar
formulation strategies may be applicable for other local
treatments. This work shows that BPMX has the potential to
play an increasingly valuable role in modern drug discovery and
development of new therapies.
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